Baidu
map

重庆启动执业药师远程药学服务和电子处方试点

2019-08-09 韩振 新华网

记者从重庆市药监局获悉,为纾解零售药店执业药师缺口大、药品处方来源难等问题,重庆在现行法规框架下,积极推进“互联网+药品流通”改革,日前正式在全市药品零售企业启动执业药师远程药学服务和电子处方试点。据重庆市药监局有关负责人介绍,重庆目前有零售药店约1.6万家,申请注册在零售药店的执业药师9400余人。该试点涵盖了全市所有药品零售连锁企业,符合条件的单体药店也可申请参加;药品零售连锁企业可自建信息平

记者从重庆市药监局获悉,为纾解零售药店执业药师缺口大、药品处方来源难等问题,重庆在现行法规框架下,积极推进“互联网+药品流通”改革,日前正式在全市药品零售企业启动执业药师远程药学服务和电子处方试点。

据重庆市药监局有关负责人介绍,重庆目前有零售药店约1.6万家,申请注册在零售药店的执业药师9400余人。该试点涵盖了全市所有药品零售连锁企业,符合条件的单体药店也可申请参加;药品零售连锁企业可自建信息平台,也可委托第三方开展远程药学服务;药品零售企业可与符合国家规定的医疗机构合作,试点实行电子处方在线服务,解决处方流转困难的问题。

此外,该试点还明确了开展远程药学服务、第三方机构的条件及要求,对执业药师队伍配备、软硬件设施设备、规章制度等进行了细化规定;明确了电子处方开具范围、保存期限,实名制问诊等具体要求;明确了药品零售企业、第三方机构及监管部门的各自职责,要求企业向监管部门开放数据接口,接受实时全程监管。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942262, encodeId=80411942262f8, content=<a href='/topic/show?id=947f8e53195' target=_blank style='color:#2F92EE;'>#药学服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87531, encryptionId=947f8e53195, topicName=药学服务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 09 16:34:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646368, encodeId=50e5164636845, content=<a href='/topic/show?id=080d5469e79' target=_blank style='color:#2F92EE;'>#执业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54697, encryptionId=080d5469e79, topicName=执业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95a523305089, createdName=维他命, createdTime=Sun Apr 26 08:34:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641748, encodeId=a4e71641e48ca, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Jan 22 06:34:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411939, encodeId=5acc1411939e9, content=<a href='/topic/show?id=f52f54e225f' target=_blank style='color:#2F92EE;'>#执业药师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54722, encryptionId=f52f54e225f, topicName=执业药师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cac32820101, createdName=3631174, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628057, encodeId=9fb9162805ef7, content=<a href='/topic/show?id=8559e0051f9' target=_blank style='color:#2F92EE;'>#电子处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70051, encryptionId=8559e0051f9, topicName=电子处方)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7e021152222, createdName=dinorsor531, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942262, encodeId=80411942262f8, content=<a href='/topic/show?id=947f8e53195' target=_blank style='color:#2F92EE;'>#药学服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87531, encryptionId=947f8e53195, topicName=药学服务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 09 16:34:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646368, encodeId=50e5164636845, content=<a href='/topic/show?id=080d5469e79' target=_blank style='color:#2F92EE;'>#执业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54697, encryptionId=080d5469e79, topicName=执业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95a523305089, createdName=维他命, createdTime=Sun Apr 26 08:34:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641748, encodeId=a4e71641e48ca, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Jan 22 06:34:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411939, encodeId=5acc1411939e9, content=<a href='/topic/show?id=f52f54e225f' target=_blank style='color:#2F92EE;'>#执业药师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54722, encryptionId=f52f54e225f, topicName=执业药师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cac32820101, createdName=3631174, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628057, encodeId=9fb9162805ef7, content=<a href='/topic/show?id=8559e0051f9' target=_blank style='color:#2F92EE;'>#电子处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70051, encryptionId=8559e0051f9, topicName=电子处方)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7e021152222, createdName=dinorsor531, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
    2020-04-26 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942262, encodeId=80411942262f8, content=<a href='/topic/show?id=947f8e53195' target=_blank style='color:#2F92EE;'>#药学服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87531, encryptionId=947f8e53195, topicName=药学服务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 09 16:34:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646368, encodeId=50e5164636845, content=<a href='/topic/show?id=080d5469e79' target=_blank style='color:#2F92EE;'>#执业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54697, encryptionId=080d5469e79, topicName=执业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95a523305089, createdName=维他命, createdTime=Sun Apr 26 08:34:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641748, encodeId=a4e71641e48ca, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Jan 22 06:34:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411939, encodeId=5acc1411939e9, content=<a href='/topic/show?id=f52f54e225f' target=_blank style='color:#2F92EE;'>#执业药师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54722, encryptionId=f52f54e225f, topicName=执业药师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cac32820101, createdName=3631174, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628057, encodeId=9fb9162805ef7, content=<a href='/topic/show?id=8559e0051f9' target=_blank style='color:#2F92EE;'>#电子处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70051, encryptionId=8559e0051f9, topicName=电子处方)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7e021152222, createdName=dinorsor531, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942262, encodeId=80411942262f8, content=<a href='/topic/show?id=947f8e53195' target=_blank style='color:#2F92EE;'>#药学服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87531, encryptionId=947f8e53195, topicName=药学服务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 09 16:34:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646368, encodeId=50e5164636845, content=<a href='/topic/show?id=080d5469e79' target=_blank style='color:#2F92EE;'>#执业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54697, encryptionId=080d5469e79, topicName=执业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95a523305089, createdName=维他命, createdTime=Sun Apr 26 08:34:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641748, encodeId=a4e71641e48ca, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Jan 22 06:34:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411939, encodeId=5acc1411939e9, content=<a href='/topic/show?id=f52f54e225f' target=_blank style='color:#2F92EE;'>#执业药师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54722, encryptionId=f52f54e225f, topicName=执业药师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cac32820101, createdName=3631174, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628057, encodeId=9fb9162805ef7, content=<a href='/topic/show?id=8559e0051f9' target=_blank style='color:#2F92EE;'>#电子处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70051, encryptionId=8559e0051f9, topicName=电子处方)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7e021152222, createdName=dinorsor531, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1942262, encodeId=80411942262f8, content=<a href='/topic/show?id=947f8e53195' target=_blank style='color:#2F92EE;'>#药学服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87531, encryptionId=947f8e53195, topicName=药学服务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Mon Dec 09 16:34:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646368, encodeId=50e5164636845, content=<a href='/topic/show?id=080d5469e79' target=_blank style='color:#2F92EE;'>#执业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54697, encryptionId=080d5469e79, topicName=执业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95a523305089, createdName=维他命, createdTime=Sun Apr 26 08:34:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641748, encodeId=a4e71641e48ca, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Jan 22 06:34:00 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411939, encodeId=5acc1411939e9, content=<a href='/topic/show?id=f52f54e225f' target=_blank style='color:#2F92EE;'>#执业药师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54722, encryptionId=f52f54e225f, topicName=执业药师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cac32820101, createdName=3631174, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628057, encodeId=9fb9162805ef7, content=<a href='/topic/show?id=8559e0051f9' target=_blank style='color:#2F92EE;'>#电子处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70051, encryptionId=8559e0051f9, topicName=电子处方)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7e021152222, createdName=dinorsor531, createdTime=Sun Aug 11 02:34:00 CST 2019, time=2019-08-11, status=1, ipAttribution=)]

相关资讯

JAMA:药师主导的患者教育有助于减少老年人的不合理用药?

2018年11月,发表于《JAMA》上的D-PRESCRIBE随机临床试验,考察了药师指导下的教育干预对老年患者停用不合理处方的影响。

严管辅助用药 药师的这个作用不可忽视

12月12日,国家卫健委发布《关于做好辅助用药临床应用管理有关工作的通知》(下称《通知》),对加强辅助用药管理,提高合理用药水平作出明确规定,这也说明了国家是下定决心严管辅助用药了。

大批非药店,将布局卖药!

今年,北京市又将在50家连锁便利店试点卖药、卖器械。接下来,将会有大批非药店布局卖药。

央视报道!药师收入将上升

据悉,药师立法已列入国家卫生立法计划,我国也将在部分公立医疗机构开展药事服务费试点工作,每张处方拟收费4元。

全国人大代表葛明华:医药分家后药师更多的参与临床用药安全工作

公立医院医改从一开始就强调推动“医药分家”,破除“以药养医”,让公立医院的药房回归公益性,随着改革的不断推进,大多数医院已经逐渐实现医药分家,那么,现在的医院、医生和药师角色有何变化呢?

无人售药铺开 药师被无视?!

无人售药铺开,药师被无视?其实真正值得可怕的是...... 1月3日,成都市药监局发布了《成都市自动售药机销售非处方药品管理规定(试行)》(以下简称《规定》)。

Baidu
map
Baidu
map
Baidu
map